ARWR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

200.76M

+7930.39%

-0.096

-93.11%

66.28M

-87.79%

-1.083

-139.38%

-1.333

+5.78%

Estimates Revision

The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2026, with the revenue forecasts being adjusted by 4.48% over the past three months. During the same period, the stock price has changed by 121.97%.

Revenue Estimates for FY2026

Revise Upward

+4.48%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+9.86%

In Past 3 Month

Stock Price

Go Up

+121.97%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast ARWR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 61.63 USD with a low forecast of 48.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

Current: 64.660

Low

48.00

Averages

61.63

High

85.00

Current: 64.660

Low

48.00

Averages

61.63

High

85.00

RBC Capital

Outperform

maintain

$52 -> $80

2025-12-11

Reason

RBC Capital

Price Target

$52 -> $80

2025-12-11

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Arrowhead to $80 from $52 and keeps an Outperform rating on the shares after meeting with its management team. The recent approval of Redemplo marks a key milestone for the organization and the company remains upbeat about the early commercial traction, the analyst tells investors in a research note. The stock has had a meaningful run recently, but the non-deal-roadshow strengthens the firm's conviction that transition to a fully integrated Biotech company may accelerate from here, especially given an organization that appears much more focused on late-stage cardiometabolic.

BofA

Buy

maintain

$62 -> $81

2025-12-09

Reason

BofA

Price Target

$62 -> $81

2025-12-09

maintain

Buy

Reason

BofA raised the firm's price target on Arrowhead to $81 from $62 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.

Morgan Stanley

Equal Weight

maintain

$48

2025-12-08

Reason

Morgan Stanley

Price Target

$48

2025-12-08

maintain

Equal Weight

Reason

Morgan Stanley reiterated an Equal Weight rating and $48 price target on Arrowhead (ARWR) after Wave (WVE) announced Phase 1 data for WVE-007 showing significant reductions in body fat while preserving lean mass in obese subjects. The firm said there is positive readthrough to Arrowhead from the competing inhibin beta E program, as Arrowhead is evaluating ARO-IHNHBE and ARO-ALK in Phase 1/2a trials, with initial data expected during the first week of January. Overall, the firm believes the data from Wave provides early validation that targeting the Activin E pathway has potential in obesity, and sees positive readthrough to Arrowhead's obesity pipeline.

H.C. Wainwright

Buy

maintain

$80 -> $85

2025-12-02

Reason

H.C. Wainwright

Price Target

$80 -> $85

2025-12-02

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Arrowhead to $85 from $80 and keeps a Buy rating on the shares. The firm says the company's "transformative" fiscal Q4 was driven by FDA approval of Redemplo for familial chylomicronemia syndrome. This marks an "inflection point" for Arrowhead's RNA interference pipeline, the analyst tells investors in a research note. H.C. Wainwright cites increased conviction that Arrowhead is entering a sustained period of clinical, regulatory, and commercial value creation for the target bump.

Morgan Stanley

Equal Weight

maintain

$45 -> $48

2025-11-26

Reason

Morgan Stanley

Price Target

$45 -> $48

2025-11-26

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Arrowhead to $48 from $45 and keeps an Equal Weight rating on the shares. Redemplo's approval in FCS last week "importantly sets the stage for meaningful label expansion into SHTG," the analyst tells investors. Phase 3 SHASTA 3 & 4 studies of plozasiran in SHTG are on track for Q3 of 2026 and management pointed to "a decent chance for success on pancreatitis," the analyst added.

Goldman Sachs

Neutral

maintain

$27 -> $48

2025-11-19

Reason

Goldman Sachs

Price Target

$27 -> $48

2025-11-19

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Arrowhead to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the announced FDA approval of Redemplo, formerly plozasiran, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, in what it calls a "best case" label scenario, the analyst tells investors in a research note. Goldman adds however that Redemplo's pricing could serve Arrowhead favorably in the near-term during the FCS launch, as both Ionis (IONS) and Arrowhead transition to the sHTG launch, the dynamic may become more nuanced.

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is -21.64, compared to its 5-year average forward P/E of -26.60. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-26.60

Current PE

-21.64

Overvalued PE

6.62

Undervalued PE

-59.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-29.62

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.47

Undervalued EV/EBITDA

-64.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

24.30

Current PS

0.00

Overvalued PS

37.99

Undervalued PS

10.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 101% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 101% over the last month.

Sold

Bought

ARWR News & Events

Events Timeline

No data

News

5.0

12-15Newsfilter

Arrowhead Pharmaceuticals Grants 141,310 RSUs to 78 New Employees

4.0

12-12NASDAQ.COM

RBC Capital Reaffirms Outperform Rating for Arrowhead Pharmaceuticals (ARWR)

2.0

12-08Benzinga

Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More

People Also Watch

Frequently Asked Questions

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 64.66 USD — it has decreased -5.54 % in the last trading day.

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

What is the price predicton of ARWR Stock?

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 256.47M USD, decreased % YoY.

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to -0.17 USD, decreased -87.59 % YoY.

What changes have occurred in the market's expectations for Arrowhead Pharmaceuticals Inc (ARWR)'s fundamentals?

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

Arrowhead Pharmaceuticals Inc (ARWR) has 711 emplpoyees as of December 17 2025.

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?

Today ARWR has the market capitalization of 8.78B USD.